Food and Drug Administration approval and has no recognized medical uses
Mar M, Morales A, Colell A, Garca-Ruiz C, Fernndez-Checa JC
We publish a Certificate of Analysis for every batch, showing the exact peptide content per vial not just a pass/fail
The results were significant: At 48 weeks, participants receiving the 12 mg dose achieved a mean weight reduction of 24.2% (approximately 58 pounds or 26.2 kg) 100% of participants on the 8 mg or 12 mg doses lost at least 5% of their body weight More than 90% of participants on the 12 mg dose lost at least 10% of their body weight Nearly half of participants on the highest dose lost 25% or more of their body weight The study also showed improvements in cardiometabolic markers including blood pressure, triglycerides, LDL cholesterol, and fasting glucose
LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) Based on 2 publication(s) in Google Scholar The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin